Hyperpolarized Xenon-129 MR Imaging of the Lung

ClinicalTrials.gov ID: NCT04662658

Public ClinicalTrials.gov record NCT04662658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Hyperpolarized Xenon-129 MR Imaging of the Lung:E-cigarette Sub-study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Over the past 10 years, electronic cigarettes (e-cigarettes, EC) have been commercialized as a "less harmful" alternative to traditional cigarettes.1,2 However, e-cigarettes are believed to cause pulmonary epithelial, endothelial and vascular dysfunction, and to cause murine phenotypes similar to those of human COPD. Recently, "spiked" vape juice has been linked to severe lung damage. Unfortunately, the effects of e-cigarettes on the human lungs are still poorly understood, especially in healthy young adults. Therefore, establishing the health effects of e-cigarettes in humans is of paramount importance to guide medical and regulatory decision making. Its widespread use and immense popularity among teenagers and young adults have caused major concern given potentially significant addictive and detrimental long-term health effects.

Study identification

NCT ID: NCT04662658
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: University of Virginia; Other
Enrollment: 24 participants

Conditions and interventions

Conditions

E-Cig Use

Interventions

Hyperpolarized Xenon -129 MRI Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 4, 2020
Primary completion: Nov 30, 2022
Completion: Nov 30, 2025
Last update posted: Dec 9, 2020

2020 – 2025

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Snyder Building 480 Ray C. Hunt Drive	Charlottesville	Virginia	22908	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04662658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 9, 2020 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04662658 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →